Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Bucknelly21on Jul 10, 2021 1:24pm
134 Views
Post# 33526774

RE:RE:RE:Weekly Report Card

RE:RE:RE:Weekly Report Card
jfm1330 wrote: This board is back to its freakin obssession with promotion and the very short term valuation of the stock. By chance you are not invested in a private company. We got a very good oncology presentation three weeks ago. We know the potential is very high, so much that it could be a once in a lifetime opportunity, a life changing investment. But at the same time, they repeated many times that it needed to be confirmed on humans. That's what they are doing now and all signals we have are pointing in the right direction. They told us recruiting was going well, that they were about to start new sites for the trial. We knew all that. They told it. Also, they are hiring intensely. Why do you think? What else do you want??? The results today? Come on!

At this point forget about a stock price that will reflect the potential. We know that this is a company that will be rewarded on real good results, and we know that cancer is not HIV lipodystrophy or a phase III in NASH that will take at least four more years. Very good results in cancer cannot be overlooked. It is just too important. It is not a marginal condition and tumor regression is impossible to ignore, even more with a platform like SORT1 that would allow a wide array of possible applications. Al that to say that if there is clear and real efficacy, the market will not ignore it. The stock will rise like a rocket, and everybody will notice. Whining about communication and promotion for two or three more months won't change anything about that.
not sure it's super about short term. It has more to do with capitalizing on your pipeline and getting a good valuation. It's hardly "short term" as their interactions with the market have been well below a good standard for years. I think it's very hard to see tons of other companies get high value while generating no revenue and still be in pre clinical trials. Not sure how you can refute that. In the end of the day we are here to see our investment potential realized. Not just wait and wait and wait. I applaud your patience but plenty have been patient long enough. Too many passes and no one holding them accountable for their failures in dealing with the market. Everyone wants the company to maximize their investment at whatever stage they are currently in. 

<< Previous
Bullboard Posts
Next >>